Edition:
India

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

102.60GBp
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
102.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,057,645
52-wk High
166.97
52-wk Low
86.50

Select another date:

Tue, Nov 14 2017

BRIEF-Vectura group announces buyback to return up to £15 million of capital to shareholders​

* ‍vectura group plc (lse: vec) ("vectura", " group"), announces that board has approved a share buyback to return up to £15 million of capital to shareholders​ Source text for Eikon: Further company coverage: (Reporting by Lawrence White)

BRIEF-Vectura confident on outlook for Novartis inhaler products

* Q3 2017 net sales of $101 million for ultibro ® breezhaler ® and $37 million for seebri ® breezhaler​

BRIEF-Vectura updates on positive Flutiform K-haler regulatory progress

* ‍FLUTIFORM BREATH-ACTIVATED K-HALER MAKES POSITIVE EUROPEAN REGULATORY PROGRESS​

BRIEF-Vectura Group posts HY revenue of 78.8 million pounds

* HY REVENUE 78.8 MILLION POUNDS VERSUS 73.9 MILLION POUNDS A YEAR AGO

BRIEF-Vectura signs VR410 agreement with Pulmatrix

* PROGRESSING DEVELOPMENT OF BRANDED GENERIC TIOTROPIUM BROMIDE PROGRAMME (VR410) FOR US MARKET, ACCELERATED THROUGH LICENCE DEAL WITH PULMATRIX

BRIEF-Vectura announces ANDA filing for US generic version of Advair Diskus

* CONFIRMS STATEMENT MADE BY PARTNER HIKMA IN RESPECT OF ANDA FILING FOR A US GENERIC VERSION OF ADVAIR DISKUS SOURCE TEXT FOR EIKON: FURTHER COMPANY COVERAGE:

Vectura signs deal with Novartis for generic U.S. lung therapy

Vectura Group Plc said on Wednesday it has signed an exclusive deal with Sandoz AG, a unit of Swiss drugmaker Novartis, to develop a generic copy of an existing combined lung therapy for the U.S. market.

Vectura signs deal with Novartis for generic U.S. lung therapy

June 28 Vectura Group Plc said on Wednesday it has signed an exclusive deal with Sandoz AG, a unit of Swiss drugmaker Novartis, to develop a generic copy of an existing combined lung therapy for the U.S. market.

BRIEF-Vectura inks new U.S. deals for generic asthma therapy​

* ‍New development and licence agreement for a U.S. inhaled generic​

Select another date: